Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Akoya Biosciences (NASDAQ:AKYA), but lowered the price target from $15 to $8.
October 24, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Akoya Biosciences, but lowered the price target from $15 to $8.
The news is directly related to Akoya Biosciences and is likely to impact its stock price. The maintenance of an Overweight rating indicates a positive outlook, but the lowering of the price target from $15 to $8 suggests a potential downside, which could negatively affect the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100